‼️ EMA's human medicines committee #CHMP :

#Nomegestrol & #chlormadinone should be used with caution to treat gynaecological conditions, as hormone replacement therapy or as oral contraceptive to reduce the risk of #meningioma.

👉 https://www.ema.europa.eu/en/news/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-chlormadinone

🐦🔗: https://nitter.eu/EMA_News/status/1565619233169588224

New measures to minimise risk of meningioma with medicines containing nomegestrol or chlormadinone - European Medicines Agency

New measures to minimise risk of meningioma with medicines containing nomegestrol or chlormadinone

European Medicines Agency

Our #safety committee, the #PRAC, recommended new measures to minimise the risk of #meningioma with 💊 containing #nomegestrol or #chlormadinone.
It also started a review of risks of neurodevelopmental disorders with #topiramate.
👉https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-4-7-july-2022

🐦🔗: https://nitter.eu/EMA_News/status/1545355046187110406

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 July 2022 - European Medicines Agency

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 July 2022

European Medicines Agency